We're a company of global stature; globally we're the market-leading provider of SABAs around the world and 1 in 6 prescriptions in the UK are for a Teva product. But we like to look at things differently to other companies in the respiratory world.
We have our own disctinctive way of doing things. We do so much more than supply generics; we are prepared to innovate. So when we found out that inhaler misuse is standing in the way of effective treatment for Asthma and COPD patients, we got to work.
